arrow
G

Giorgina Specchia

university of bari (aldo moro)
H指数:75
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chimeric Antigen Receptor-T Cells Fate after Infusion: Cellular Kinetics and Molecular Monitoring

嵌合抗原受体-T细胞输注后的命运:细胞动力学与分子监测

2026-06-240
OAAI
One Grammar, Many Labels: Revisiting the Continuum of Myeloid Neoplasms

一种语法,多种标签:重新审视髓系肿瘤的连续统

2026-05-190
OA
Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study

年龄和性别对慢性髓性白血病患者在一线治疗中分子反应的影响:一项意大利CML网络队列研究

2026-04-180
OAAI
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?

低甲基化剂单独或联合维尼托克治疗高龄急性髓系白血病患者: 更少的治疗,更好的护理?

2026-01-110
OAAI
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study
2026-01-110
OA
Correction: RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications

更正:RUNX1A异构体在急性髓系白血病中过度表达,并与FLT3内部串联重复突变相关。

2025-11-030
OAAI
Splenomegaly in de novo acute myeloid leukemia is associated with ASXL1 mutations together with a distinct clinical and gene expression profile

新诊断急性髓系白血病中的脾肿大与ASXL1突变相关,并伴有独特的临床和基因表达谱。

2025-10-230
OAAI
Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese

单次与多次自体干细胞移植以及来那度胺维持治疗与无维持治疗在 newly-diagnosed 多发性骨髓瘤患者中的比较:来自 Rete Ematologica Pugliese 的真实世界数据,回顾二十三年来的研究进展

2025-10-100
OA
RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications

RUNX1A异构体在急性髓系白血病中过表达,并与FLT3内部串联重复相关。

2025-07-150
OA
CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or < 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

慢性粒细胞白血病患者在12个月时未达到BCR::ABL1 ≤ 1%(主要分子缓解,MMR)或在24个月时未达到BCR::ABL1 < 0.1%,其生存率显著较差,但并非由于CML相关死亡:一项意大利真实世界观察性研究的数据

BLOOD
IF23.1
2024-11-050
PRE
Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50-60 Years: A Campus CML Study

基线特征、治疗选择及早期一线TKI永久停药在50-60岁新诊断慢性髓性白血病患者中的研究:一项Campus CML研究

BLOOD
IF23.1
2024-11-050
PRE
IRF4 dysregulation in chronic myelomonocytic leukemia: another brick in the wall of myelodysplastic/myeloproliferative neoplasms
2024-08-150
PRE
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial
2024-06-154
OAAI
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience

基于Daratumumab的多发性骨髓瘤加髓外浆细胞瘤或骨骼旁浆细胞瘤患者的方案: 意大利多中心观察性临床经验的初步随访

2024-05-280
PRE
TNFRSF13B gene mutation in familial acute myeloid leukemia: A new piece in the complex scenario of hereditary predisposition?
2023-08-033
OAAI
Case report: biallelic DNMT3A mutations in acute myeloid leukemia
2023-06-280
OAAI
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML
CANCER
IF5.1
2023-06-246
OAAI